Probiotics & prebiotics

Probiotics are a $60-billion industry built largely on two bacterial genera studied since the 1970s. Before spending money on supplements, it helps to know what the evidence shows, and where marketing has outrun the science.

The vocabulary matters

Four terms get conflated constantly. A probiotic is a live microorganism you ingest. A prebiotic is the substrate that feeds your gut microbes, insoluble fiber, inulin, polyphenols. A postbiotic is what gut microbes produce: butyrate, short-chain fatty acids, serotonin. A synbiotic combines pre- and probiotic in one formulation. Cutcliffe's clinical framework defines these precisely because confusing them leads to confused purchasing decisions [1].

What the evidence supports

The two strongest findings in this space come from controlled trials, not observational studies.

Fermented foods, not probiotic capsules, raised gut microbiome diversity and reduced markers of systemic inflammation in a well-designed RCT [2]. That's a meaningful distinction: whole fermented foods deliver a matrix of live organisms, postbiotics, and nutrients that no capsule replicates.

Fecal microbiota transplant (FMT) for recurrent Clostridioides difficile infection shows the most dramatic clinical outcomes in gut medicine. A single FMT infusion resolved infection in roughly 81% of patients; a second infusion raised that to about 94%. Vancomycin, the standard antibiotic, resolved 31% [3]. FMT is not a consumer intervention, it's a medical procedure, but those numbers illustrate how powerfully microbiome composition affects disease.

Dietary fiber is the most reliable broad microbiome-positive intervention, and the foundational substrate for short-chain fatty acid production [4]. This is mechanistically consistent across a large literature, not a single trial finding.

Why Lactobacillus and Bifidobacterium dominate shelves

These genera are facultative anaerobes: they survive in oxygen, which makes them cheap and easy to manufacture at scale. They've been on the market since the 1970s and are FDA-grandfathered as "generally recognized as safe," meaning new strains of these genera don't require the same approval pathway as novel organisms [1]. More physiologically interesting strict anaerobes, Akkermansia muciniphila, for instance, require fully anaerobic manufacturing infrastructure, which is expensive. The market reflects manufacturing economics as much as clinical evidence.

For Lactobacillus and Bifidobacterium, the best-supported outcome is modest GI symptom relief: less bloating, gas, and constipation. Systemic benefits are weaker and much less consistent [1].

CFU is a flawed metric

Colony-forming units measure how many bacteria form visible colonies on a petri dish. Problems: CFU counts only live cells, ignoring dead cells that may still have biological activity; the number on the label often reflects viability at time of manufacture, not at end of shelf life (which can be substantially lower after storage); and testing methods vary enough across manufacturers that label numbers aren't directly comparable [1].

Flow cytometry, staining cells by membrane integrity and counting live, damaged, and dead fractions separately, is more informative. One company, Pendulum, uses a proprietary metric called AFU (active fraction units) based on this approach. Cutcliffe's analysis notes this more accurately reflects live-cell content than CFU [1]. Critical caveat: Pendulum invented the AFU term. This is a severe conflict of interest, and AFU is not standardized across the industry, so it cannot be compared to any other company's claims.

Where the evidence is contested

Gut-brain axis supplementation. The connection between gut microbes and brain function is real and actively researched. Cutcliffe frames the idea that specific probiotic strains reliably change mood or stress as early and speculative, there are no replicated RCTs establishing this in humans [1]. Manufacturers of "psychobiotic" products cite mechanistic plausibility, not clinical outcomes. Neither side disputes the underlying biology; the dispute is whether current supplements can reliably move those levers.

Post-antibiotic recolonization. Broad-spectrum antibiotics depopulate the gut microbiome regardless of what organism they're targeting. High fiber and polyphenol intake during and after a course is consistent with established fiber literature [4] and gives surviving microbiome substrate the best conditions to recover. Whether specific probiotic supplementation during antibiotic treatment improves long-term recovery is uncertain, no primary RCT has established this. Even Cutcliffe, who sells probiotics, frames fiber as primary and supplements as secondary [1].

Personalized microbiome testing. Consumer gut-composition tests face a biological problem: microbiome composition varies substantially between individuals and shifts within the same person over time. A single snapshot has limited clinical utility, and actionable guidance from these tests remains modest [1].

The through-line across the strongest evidence: food diversity, fiber, and fermentation outperform supplements in the data we have. Supplements may have a role for specific GI symptoms in specific people, but they're not a substitute for the substrate your microbiome runs on.

References

1. raw/attia/attia283-gut-microbiome-probiotics.txt ✓ FULL TRANSCRIPT READ (173k chars; Batch G second half ingested 2026-09-06)
2. Wastyk et al. 2021, Cell — fermented foods vs fiber (diversity) · PubMed 34256014
3. van Nood et al. 2013 NEJM — FMT vs vancomycin for recurrent C. difficile: 81%/94% vs ~23–31% · PubMed 23323867
4. Reynolds et al. 2019, Lancet — dietary fibre & health outcomes · PubMed 30638909